Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Macaya Douoguih"'
Autor:
Jerald, Sadoff, Glenda, Gray, An, Vandebosch, Vicky, Cárdenas, Georgi, Shukarev, Beatriz, Grinsztejn, Paul A, Goepfert, Carla, Truyers, Hein, Fennema, Bart, Spiessens, Kim, Offergeld, Gert, Scheper, Kimberly L, Taylor, Merlin L, Robb, John, Treanor, Dan H, Barouch, Jeffrey, Stoddard, Martin F, Ryser, Mary A, Marovich, Kathleen M, Neuzil, Lawrence, Corey, Nancy, Cauwenberghs, Tamzin, Tanner, Karin, Hardt, Javier, Ruiz-Guiñazú, Mathieu, Le Gars, Hanneke, Schuitemaker, Johan, Van Hoof, Frank, Struyf, Macaya, Douoguih, Marcus, Zervos
Publikováno v:
New England Journal of Medicine. 384:2187-2201
The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.In an internation
Autor:
Roland Zahn, Carlos Fierro, Maarten Leyssen, Marrit N. Habets, Kayvon Modjarrad, Rafael A. Larocca, Carla Truyers, Hanneke Schuitemaker, Leslie van der Fits, Diane G. Kanjilal, Kristi Lynn Williams, Nadine C. Salisch, Jenny Hendriks, Kathryn E. Stephenson, Macaya Douoguih, Johan Van Hoof, Dan H. Barouch, Conor P. Cahill, Freek Cox, Dirk Heerwegh, Jinyan Liu, Peter Abbink, Lauren Peter, Rafael De La Barrera
Publikováno v:
Annals of Internal Medicine. 174:585-594
BACKGROUND: Zika virus (ZIKV) may cause severe congenital disease after maternal-fetal transmission. No vaccine is currently available. OBJECTIVE: To assess the safety and immunogenicity of Ad26.ZIKV.001, a prophylactic ZIKV vaccine candidate. DESIGN
Autor:
Georgi Shukarev, Helen R Wagstaffe, Jeroen N Stoop, Viki Bockstal, Eleanor M. Riley, Kerstin Luhn, Matthew D. Snape, Andrew J. Pollard, Martin R. Goodier, Macaya Douoguih, Elizabeth A. Clutterbuck
Publikováno v:
The Journal of Infectious Diseases
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Background Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent
Publikováno v:
The New England Journal of Medicine
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Manufacturer’s Response The manufacturer of the Ad26.COV2.S vaccine against Covid-19 comments on recent reports of thrombosis, including ...
Autor:
Catherine Jacob-Dolan, Michael S. Seaman, Carolyn D. Alonso, Macaya Douoguih, Hanneke Schuitemaker, Ruvandhi R. Nathavitharana, Jinyan Liu, Lisa H. Tostanoski, Roger L. Shapiro, Jerald C. Sadoff, Kate Jaegle, Shivani A. Patel, Katherine E. Yanosick, Abishek Chandrashekar, Katherine McMahan, Jessica L Ansel, Chen S. Tan, Dan H. Barouch, Diane G. Kanjilal, Jingyou Yu, Morgana Souza, Douglas A. Lauffenburger, Anna Tyler, Anne Marit de Groot, Caitlin J. Guiney, Frank Struyf, Mathieu Le Gars, Connor Bradshaw, Kathryn E. Stephenson, Joseph P. Nkolola, Carla Truyers, Zhenfeng Li, Rebecca Zash, Boris Julg, Carolin Loos, Caroline Atyeo, Galit Alter, Johan Van Hoof, Dirk Heerwegh, Erica N. Borducchi, Makda S. Gebre, Lauren Peter, Tatenda Makoni, Ahmed Abdul Azim
Publikováno v:
JAMA
Importance Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c08377b16842fb53684d63f63c34e97
https://europepmc.org/articles/PMC7953339/
https://europepmc.org/articles/PMC7953339/
Autor:
Hilary S. Whitworth, Pontiano Kaleebu, George PrayGod, Macaya Douoguih, Saidi Kapiga, Deborah Watson-Jones, Dickson Anumendem, Kerstin Luhn, Samuel E. Kalluvya, Cynthia Robinson, Georgi Shukarev, Daniela Manno, Viki Bockstal, Zacchaeus Anywaine, Heiner Grosskurth
Publikováno v:
The Journal of Infectious Diseases
Background Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccina
Autor:
Hanneke Schuitemaker, Jerald C. Sadoff, Gert Scheper, Jeroen Stoop, Emmanuel Cormier, Pierre Van Damme, Isabel Leroux-Roels, Johan Van Hoof, Anne Marit de Groot, Wim Van Damme, Frank Struyf, Sarah Tete, Carla Truyers, Mathieu Le Gars, Jenny Hendriks, William T. Smith, Murray Kimmel, Dirk Heerwegh, Kristen W. Cohen, Georgi Shukarev, Jan de Hoon, M Juliana McElrath, Macaya Douoguih, Dan H. Barouch, Stephen C De Rosa, Pieter-Jan Berghmans, Kathryn E. Stephenson
Publikováno v:
The New England Journal of Medicine
New England Journal of Medicine
NEW ENGLAND JOURNAL OF MEDICINE
The New England journal of medicine
New England Journal of Medicine
NEW ENGLAND JOURNAL OF MEDICINE
The New England journal of medicine
BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinan
Autor:
Frank Struyf, Mathieu Le Gars, Ian M. Kaplan, Tochi Anioke, Catherine Jacob-Dolan, Erica N. Borducchi, Katherine McMahan, Macaya Douoguih, Florian Krammer, Sally Shin, Michelle A. Lifton, Abishek Chandrashekar, Joseph P. Nkolola, Lisa H. Tostanoski, David R. Martinez, Aiquan Chang, Jinyan Liu, Paul A. Fields, Kathryn E. Stephenson, Anne Marit de Groot, Jerald C. Sadoff, Harlan Robins, Hanneke Schuitemaker, Dan H. Barouch, Jingyou Yu, Ralph S. Baric, Dirk Heerwegh, Fatima Amanat, Caroline Atyeo, Galit Alter, Johan Van Hoof
Publikováno v:
Nature
The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c48aa07cacbb44fbd291d2931e461c0
Autor:
Bart Spiessens, Ramon Roozendaal, Liesbeth Dekking, Maria Grazia Pau, Cynthia Robinson, Dominika N. Czapska-Casey, Yvonne Wollmann, Thierry Van Effelterre, Viki Bockstal, Eline Dekeyster, Roland Zahn, Jeroen N Stoop, Kerstin Luhn, Jan Serroyen, Luis D. Giavedoni, Jenny Hendriks, Sarah Janssen, Maarten Leyssen, Ben Van Baelen, Hanneke Schuitemaker, Ricardo Carrion, Daniel Splinter, An Vandebosch, Jerry Sadoff, Ariane Volkmann, Nadia Verbruggen, Macaya Douoguih, Laura Solforosi, Benoit Callendret
Publikováno v:
NPJ VACCINES
npj Vaccines
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-11 (2020)
npj Vaccines
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-11 (2020)
It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vaccine immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a435e1265a441954725ed3930a761f9
http://hdl.handle.net/1887/3562934
http://hdl.handle.net/1887/3562934
Autor:
Andrew J Pollard, Odile Launay, Jean-Daniel Lelievre, Christine Lacabaratz, Sophie Grande, Neil Goldstein, Cynthia Robinson, Auguste Gaddah, Viki Bockstal, Aurelie Wiedemann, Maarten Leyssen, Kerstin Luhn, Laura Richert, Christine Bétard, Malick M Gibani, Elizabeth A Clutterbuck, Matthew D Snape, Yves Levy, Macaya Douoguih, Rodolphe Thiebaut, Christopher McShane, Benoit Callendret, Stephanie Dincq, Camille Ferrault, Siew Pin Chai, Maire Paule Gyselen, Marleen van Looveren, Sylvia van Ballert, Tinne de Cnodder, Len Roza, Chiara Forcheh, Kate Stevens, Carmela Mastrandrea, Sanne de Ridder, Rachana Gundluru, Nathalie Swales, Vanessa Errijegers, Wouter Willems, Veronika Roorda, Nicola Orzabal, Magdalena Assenberg, Karine Vialatte, Frédéric Remblier, Elodie Porcar, Anton Ottavi, Eugénie Destandau, Christine Schwimmer, Laetitia Moinot, Cédrick Wallet, Florence Allais, Hélène Savel, Naouel Nedjaai, Anaïs Maugard, Nehza Lenzi, Pierre Loulergue, Mathilde Bahuaud, Fabrice Lainé, Bruno Laviolle, Nolwenn Boissel, Elise Thébault, David Vallée, Jean-François Nicolas, Sophie Gilbert, Karima Dahel, Karen Sagorny, Frédéric Lucht, Stéphane Paul, Alice Haccourt Chanavat, Florent Charra, Catherine Mutter, Monique Lambour, Caroline Muller, Anne Hutt-Clauss, Olivia Aranda, Louis Bernard, Valérie Gissot, Marie-Charlotte Hallouin-Bernard, Alain Goudeau, Steve Suzzoni, Eva Auostin, Lysiane Brick, Jose-Luis Lopez-Zaragoza, Giovanna Melic, Murial Carvalho, Chrystel Chesnel, Hakim Hocini, Aurélie Wiedemann, Laurent Hanot, Véronique Rieux, Adeep Puri, Temitope Adeloye, Malcolm Boyce, Jeremy Dennison, Inge Loewenstein, Omar Sahgal, Frans van den Berg, Wendy Calvert, Mary Faldon, Bruce McClain, Marie-Lousie Newell, Geert Molenberghs
Publikováno v:
The Lancet Infectious Diseases
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, ⟨10.1016/S1473-3099(20)30476-X⟩
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, ⟨10.1016/S1473-3099(20)30476-X⟩
Summary Background To address the unmet medical need for an effective prophylactic vaccine against Ebola virus we assessed the safety and immunogenicity of three different two-dose heterologous vaccination regimens with a replication-deficient adenov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43c24659b62a3ec06bc9708186876d5
http://hdl.handle.net/20.500.12278/26684
http://hdl.handle.net/20.500.12278/26684